GlassScriptPhysician profile
Neal Ramesh Patel
NPI 1174767032
$5,569.58
in general payments reported to CMS, 2019-2025
30 companies · $1,568 in 2025
The $1,568 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $312 · 2021: $601 · 2022: $865 · 2023: $988 · 2024: $728 · 2025: $1,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190 · Education: $92.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.34 |
| Education | $92.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,707.82 | 2019-2025 | |
| Genzyme Corporation | $808.92 | 2022-2025 | |
| Janssen Biotech, INC. | $515.71 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $507.96 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $440.25 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.59 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Celgene Corporation | $194.68 | 2021-2024 | Zeposia |
| Pfizer INC. | $194.05 | 2019-2025 | |
| Ardelyx, INC. | $147.49 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $81.60 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $81.50 | 2020-2021 | |
| Lilly USA, LLC | $73.47 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $71.48 | 2025 | Rezdiffra |
| Ucb, INC. | $68.49 | 2019 | |
| Sandoz INC. | $52.33 | 2023 | Hyrimoz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $46.95 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $44.52 | 2024 | Voquezna |
| Alfasigma USA, INC. | $29.68 | 2020-2021 | |
| Daiichi Sankyo INC. | $29.54 | 2020-2021 | |
| Redhill Biopharma INC. | $29.26 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $28.78 | 2024 | |
| Novo Nordisk INC | $25.43 | 2025 | Wegovy |
| Insmed, INC. | $19.90 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.91 | 2025 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $17.52 | 2025 | Iqirvo |
| Astrazeneca Pharmaceuticals LP | $16.69 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.43 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.85 | 2022 | |
| Gilead Sciences, INC. | $14.10 | 2020 | |
| Ferring Pharmaceuticals INC. | $13.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.